Literature DB >> 31504527

Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy.

Zili Lin1, Huiyi Wu1, Yiming Fu2, Shixue Dai3,4.   

Abstract

BACKGROUND: Conventional medicine for the treatment of IBD is prevailingly composed of sulfadiazine, 5-aminosalicylic acid, glucocorticoid, and immunosuppressants, which have the merits of alleviating intestine inflammation, but long-term use of these drugs may cause toxic side effects; additionally, these drugs may be expensive. In the pursuit of novel and more economic therapies, patients may increasingly look at complementary and alternative medicine (CAM). Recently, CAM is increasingly favored by the general public on account of its safety, low toxicity, and effectiveness. As a branch of CAM, herbal plants and their extracts have a significant effect on the treatment of IBD. Treatment of IBD with herbaceous plants has been reported, but specific mechanisms and effects have not yet been elaborated.
METHODS: English abstracts were identified in PubMed and Science Direct by multiple search terms, such as "herbal," "CAM," "IBD," "ulcerative colitis," "abdominal pain," and so on. Full-length articles were selected for review.
RESULTS: Herbaceous plants and their extracts have been shown to be effective against IBD in many studies, and herbaceous plants may be effective in treating symptoms such as abdominal pain, diarrhea, mucus, and bloody stools.
CONCLUSIONS: Herbal medications could be used as a complementary and alternative treatment for IBD, but they require more rigorous scientific testing.
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  complementary and alternative medicine; herbal medications; inflammatory bowel disease

Mesh:

Substances:

Year:  2019        PMID: 31504527     DOI: 10.1093/ibd/izz190

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  4 in total

1.  Gallincin ameliorates colitis-associated inflammation and barrier function in mice based on network pharmacology prediction.

Authors:  De-Jun Cui; Xiao-Lan Yang; Shujiro Okuda; Yi-Wei Ling; Zhu-Xue Zhang; Qi Liu; Wen-Qiang Yuan; Fang Yan
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

2.  Quyu Shengxin Decoction Alleviates DSS-Induced Ulcerative Colitis in Mice by Suppressing RIP1/RIP3/NLRP3 Signalling.

Authors:  Chuang Wu; Haojie Yang; Changpeng Han; Qingming Wang; Haiyan Zhang; Ting Huang; Wenjing Mao; Cheng Tang; Wenjun Zhao; Zhiming Zhu; Jing Xu; Wei Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-20       Impact factor: 2.629

3.  Colon-specific delivery of isoliquiritigenin by oral edible zein/caseate nanocomplex for ulcerative colitis treatment.

Authors:  Meng Xiao; Shuyang Wu; Yanfen Cheng; Jiaqi Ma; Xi Luo; Liang Chang; Chen Zhang; Jianping Chen; Liang Zou; Yu You; Jinming Zhang
Journal:  Front Chem       Date:  2022-09-09       Impact factor: 5.545

4.  A comparison of the efficacy and safety of complementary and alternative therapies for ulcerative colitis: A protocol for systematic review and meta-analysis.

Authors:  Meiqi Lu; Ting Zhang; Zhen Lu; Wei Wang; Ting Chen; Zhiqun Cao
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.